Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter AI-driven partnership worth $5.3bn

The deal will focus on advancing pre-clinical candidates for chronic conditions

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

The vaccine is already approved in the US for use in adults aged 60 years and older

- PMLiVE

Duchenne muscular dystrophy – diagnosis, clinical development and global research

Its impact on patients, available treatments and why early diagnosis is essential

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

Patient partnerships for life

It’s not about just engaging with patients, it is about co-creating with patients, making them integral at every stage

Virtual Grant Writing & Review – Engaging Your Advisors Creatively

Boost your research initiatives! Discover how to creatively manage virtual grant writing & review programs with your KOLs, identifying key topics & streamlining proposal approvals. Foster impactful collaborations. Watch

Impetus Digital

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

Better together – accelerating innovation and access to rare disease treatments

Advancing rare disease research through global collaborations and unified clinical trials

- PMLiVE

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links